Drug Discovery & Development | Gilead's Hep C Drug Sovaldi Approved in EU Drug Discovery & Development Sovaldi has been studied in hepatitis C virus (HCV) genotypes 1-6. The efficacy of Sovaldi has been established in patients with genotypes 1-4, in those awaiting liver transplantation and those with HCV/HIV-1 co-infection. The clinical data supporting ... Sovaldi OK'd for marketing throughout European Union |
